CAMBRIDGE, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on April 1, 2026, it awarded inducement grants to 13 new employees under Intellia's 2024 Inducement Plan, as amended, as a material inducement to employment.

Intellia Therapeutics is getting around a recent major regulatory setback. However, the stock still faces several potential issues.

CAMBRIDGE, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on March 1, 2026, it awarded inducement grants to six new employees under Intellia's 2024 Inducement Plan as a material inducement to employment.

Shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA - Get Free Report) have received an average recommendation of "Hold" from the twenty-one analysts that are presently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have issued a buy rating

Ark Invest bought shares of MercadoLibre, Intellia Therapeutics, and Generate Biomedicines on Monday. MercadoLibre and Intellia Therapeutics are trading 33% and 45% below their 52-week highs, respectively.

CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced details about its presentation of four posters at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting (AAAAI) that took place this past weekend in Philadelphia, Pennsylvania.

Intellia Therapeutics Inc. (NASDAQ: NTLA) shares are up on Monday following the FDA's decision to lift the clinical hold on its MAGNITUDE Phase 3 clinical trial.

Intellia Therapeutics said on Monday the U.S. Food and Drug Administration has removed a clinical hold on the late-stage clinical trial for its experimental gene therapy for a heart disease.

CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on the Investigational New Drug application (IND) for the MAGNITUDE Phase 3 clinical trial of nexiguran ziclumeran (nex-z) for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM).

NTLA shares jump after fourth-quarter earnings and revenues exceed expectations. The company focuses on lonvo-z and nex-z pipeline programs.